EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

PharmVar GeneFocus : NAT2 — Genetic Variation and Updated Nomenclature

Georgia Papanikolaou iD, Estella S Poloni iD, José A G Agúndez iD, Raquel L F Teixeira iD, Erin C Boone iD, Adalberto Rezende Santos iD, Michelle Whirl-Carrillo iD, Katrin Sangkuhl iD, Teri E Klein iD, Mariam R Habil iD, Giannoulis Fakis iD, Rodney F Minchin iD und 3 weitere

Clinical Pharmacology & Therapeutics · 2026-04 · 119 (4) · 859-871

DOI: 10.1002/cpt.70168 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 23.12.2025. Verfasst von Georgia Papanikolaou und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece. Hauptthemen laut MEDLINE: Arylamine N-Acetyltransferase, Terminology as Topic, Genetic Variation, Pharmacogenomic Variants. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIEHS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Pharmacogene Variation Consortium (PharmVar) provides nomenclature for the highly polymorphic human N‐acetyltransferase 2 ( NAT2) gene. NAT2 metabolizes several clinically used drugs including isoniazid, hydralazine, amifampridine, procainamide, and sulfonamides such as dapsone, and also some highly carcinogenic arylamines. Systematic nomenclature describing NAT2 variation is essential for pharmacogenetic testing, genotype interpretation, and translation to phenotype in research and clinical settings. This GeneFocus provides an overview of NAT2 variation and describes important changes to its star allele‐based nomenclature that were made as it was transitioned to PharmVar in March 2024. We also highlight and discuss challenges regarding the characterization of allelic variation and determination of allele frequencies across world populations. The “new” NAT2 PharmVar nomenclature is utilized by ClinPGx (formerly PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arylamine N-AcetyltransferaseTerminology as TopicGenetic VariationPharmacogenomic VariantsHumansPharmacogeneticsGene FrequencyGenotype

Substanzen

Arylamine N-AcetyltransferaseNAT2 protein, human

Autor:innen und Institutionen

  • Department of Molecular Biology and Genetics, Democritus University of Thrace, Alexandroupolis, Greece.
  • Department of Genetics and Evolution (GENEV), Institute of Genetics and Genomics Geneva (iGE3), University of Geneva, Geneva, Switzerland.
  • Universidad de Extremadura, University Institute of Molecular Pathology Biomarkers, Cáceres, Spain.
  • Laboratory of Molecular Biology Applied to Mycobacteria, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil.
  • Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute (CMRI), Kansas City, Missouri, USA.
  • Department of Biomedical Data Science, Stanford University, Stanford, California, USA.

ORCID-Profile: Georgia Papanikolaou, Estella S Poloni, José A G Agúndez, Raquel L F Teixeira, Erin C Boone, Adalberto Rezende Santos, Michelle Whirl-Carrillo, Katrin Sangkuhl, Teri E Klein, Mariam R Habil, Giannoulis Fakis, Rodney F Minchin, David W Hein, Sotiria Boukouvala, Andrea Gaedigk

Förderung

  • NIEHS NIH HHS

Zitieren

APA

Papanikolaou, G., Poloni, E. S., Agúndez, J. A. G., Teixeira, R. L. F., Boone, E. C., Rezende Santos, A., Whirl-Carrillo, M., Sangkuhl, K., Klein, T. E., Habil, M. R., Fakis, G., Minchin, R. F., Hein, D. W., Boukouvala, S., & Gaedigk, A. (2026). PharmVar GeneFocus : NAT2 — Genetic Variation and Updated Nomenclature. Clinical Pharmacology & Therapeutics, 119(4), 859-871. https://doi.org/10.1002/cpt.70168

Vancouver

Papanikolaou G, Poloni ES, Agúndez JAG, Teixeira RLF, Boone EC, Rezende Santos A, et al. PharmVar GeneFocus : NAT2 — Genetic Variation and Updated Nomenclature. Clinical Pharmacology & Therapeutics. 2026;119(4):859-871. doi:10.1002/cpt.70168

BibTeX
@article{Papanikolaou2026,
  author = {Papanikolaou, Georgia and Poloni, Estella S and Agúndez, José A G and Teixeira, Raquel L F and Boone, Erin C and Rezende Santos, Adalberto and Whirl-Carrillo, Michelle and Sangkuhl, Katrin and Klein, Teri E and Habil, Mariam R and Fakis, Giannoulis and Minchin, Rodney F and Hein, David W and Boukouvala, Sotiria and Gaedigk, Andrea},
  title = {PharmVar GeneFocus : NAT2 — Genetic Variation and Updated Nomenclature},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {4},
  pages = {859--871},
  doi = {10.1002/cpt.70168}
}
Kostenlos starten →